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ABSTRACT
Background. Some kidney diseases tend to recur in the renal
allograft after transplantation. We studied the risk of graft
loss among primary renal diseases known for their high risk
of recurrence and compared it with that of patients with hy-
poplasia and/or dysplasia.
Methods. Within the European Society of Paediatric Ne-
phrology and European Renal Association and European
Dialysis and Transplant Association (ESPN/ERA-EDTA) reg-
istry, we studied children from 33 countries who received a
kidney transplant before the age of 20 between 1990 and
2009. Patients were censored after 5 years of follow-up and
cumulative incidence competing risk analysis was used to cal-
culate survival curves.
Results. Patients with focal and segmental glomerulosclerosis
(FSGS), haemolytic uraemic syndrome (HUS), membrano-
proliferative glomerulonephritis Type I or II (MPGN), IgA
nephropathy or Henoch Schönlein Purpura (HSP/IgA) or
systemic lupus erythomatosus (SLE) underwent pre-emptive
transplantation signiﬁcantly less often than patients with hy-
poplasia and/or dysplasia. The rate of living donation was
lower among patients with FSGS and SLE than in patients
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with hypoplasia and/or dysplasia. In comparison with hypo-
plasia and/or dysplasia patients with a risk of 14.4%, the 5-
year risk of graft loss was signiﬁcantly increased in patients
with FSGS (25.7%) and MPGN (32.4%) while it was not sig-
niﬁcantly increased in children with HUS (18.9%), HSP/IgA
(16.3%) or SLE (20.3%). One-year graft survival strongly im-
proved among HUS patients from 17.1% in 1995–1999 to
3.6% in 2005–2009 and was not accompanied by a decrease
in the number of transplantations.
Conclusion. The risk of graft loss is increased among speciﬁc
causes of renal failure with a high risk of post-transplant re-
currence. It seems likely that, due to anticipation of such risk,
physicians perform less pre-emptive transplantation and
provide fewer grafts from living related donors in patients
with these conditions. Improved risk stratiﬁcation by phys-
icians, resulting in the identiﬁcation of patients with HUS at
higher or lower risk of recurrence, might explain the much
improved graft survival rates.
INTRODUCTION
Renal transplantation is the treatment of choice for children
and adults with end-stage renal disease. However, it is not
always an ultimate solution, as some kidney diseases tend to
recur in the renal allograft and disease recurrence is more fre-
quent in children than in adults [1]. One could make a dis-
tinction between kidney diseases that tend to have a ‘full
blown’ recurrence leading to graft loss, and kidney diseases
that recur without apparent increased risk of graft loss [1].
Although several studies reported an increased risk of graft
loss among very rare speciﬁc kidney diseases, they were
usually based on a very limited number of patients and were
compared with the general risk of graft loss.
In the present paper we describe the real-life risk of graft
loss among kidney diseases known to be associated with a high
risk of disease recurrence and subsequent graft loss [idiopathic
focal and segmental glomerulosclerosis (FSGS), haemolytic
uraemic syndrome (HUS), membranoproliferative glomerulo-
nephritis (MPGN) and mesangiocapillary glomerulonephritis
Type I and II (dense deposit disease)] together with those
kidney diseases with a high risk of disease recurrence but in
which the risk of graft loss is expected to be low(er), namely
IgA nephropathy and Henoch Schönlein Purpura (HSP/IgA)
and systemic lupus erythomatosus (SLE). We compared these
risks with those of patients with hypoplasia or dysplasia (ex-
cluding patients with obstructive uropathy or reﬂux), who do
not suffer from disease recurrence. We wanted to determine (i)
patient characteristics at the time of transplantation for individ-
uals with speciﬁc kidney diseases; (ii) the risk of graft loss for
these kidney diseases and (iii) subgroups that were at higher or
lower risk and any recent time trend in the risk of graft loss.
MATERIALS AND METHODS
Within the framework of the European Society of Paediatric
Nephrology and European Renal Association and European
Dialysis and Transplant Association (ESPN/ERA-EDTA)
Registry, countries collected individual patient data on the
date of birth, gender, treatment modality at the start of renal
replacement therapy (RRT) and changes in RRT modality
[2]. Patients aged 20 years or less who received a transplant
between 1 January 1990 and 31 December 2009 were in-
cluded in the analysis. Austria, Belgium, Belarus, Bulgaria,
Croatia, Czech Republic, Denmark, Estonia, Finland, France,
FYR of Macedonia, Greece, Hungary, Iceland, Italy, Latvia,
Lithuania, Montenegro, the Netherlands, Norway, Poland,
Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain,
Sweden, Switzerland, Turkey, Ukraine and the UK all con-
tributed to the study. To avoid a selection bias among
patients, we limited our analyses to time periods for which
countries contributed complete data. The kidney diseases
were coded according to the ERA-EDTA coding system [3]:
FSGS (Code 11), HUS (Code 88), MPGN Type I (Code 15),
MPGN Type II (Code 13), HSP/IgA (Code 12 and 85), SLE
(Code 84), hypoplasia and/or dysplasia (Codes 60, 61, 63,
and 66). In the ESPN/ERA-EDTA registry, insufﬁcient data
were available on the recurrence of the disease as the cause of
graft loss. We assumed that any additional risk of graft loss
among diseases known for their increased risk of disease re-
currence, when compared with that among patients with hy-
poplasia and/or dysplasia would be due to disease recurrence.
Patients were censored after living with a transplant at the
end of the observation period, reaching 31 December 2009,
being transferred to a centre for treatment of adult patients
without information on the follow-up or after death without
prior dialysis (assumed with a functioning graft).
Analyses
Analyses were performed using SAS 9.2. Differences
between categorical variables were calculated using the χ2
test, whereas differences between continuous variables were
calculated using a t-test. The associations between patient
characteristics at the time of transplantation and the likeli-
hood of transplantation were calculated using logistic
regression analyses, resulting in odds ratios (ORs) and 95%
conﬁdence intervals (95% CIs). To study 1- and 5-year graft
survival and to determine the percentage of graft survival,
survival curves were calculated taking the competing event
death into account by using cumulative incidence competing
risk analysis [4]. In this analysis, signiﬁcance was determined
using P-values calculated according to Pepe and Mori [5].
Trends over time were only calculated among those countries
providing complete follow-up data between 1995 and 2009
and only those causes of renal failure were selected in whom
at least 20 patients per era received a renal allograft. Cox-
regression models were used to calculate the risk of graft loss
at 1 and 5 years. The obtained hazard ratios (HRs) were ad-
justed for age at the start of RRT, age at transplantation,
gender and era of transplantation. For different subgroups,
the Cox-regression analyses were repeated. A sensitivity ana-
lyses was performed including adjustment for living versus
deceased donation. P-values of <0.05 were considered as stat-
istically signiﬁcant.
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RESULTS
In the ESPN/ERA-EDTA registry between 1 January 1990
and 31 December 2009, 5892 patients with end-stage renal
failure received a renal transplant. The 3937 patients who suf-
fered from other causes of renal failure than the ones under
study were excluded. Therefore, 1955 patients were included
in the present analyses. Patient characteristics are shown in
Table 1.
Characteristics at time of transplantation
Patients with a high risk of recurrence of their underlying
condition underwent pre-emptive transplantation signiﬁ-
cantly less frequently than those with hypoplasia and/or dys-
plasia, even after adjustment for age, gender and time period
(Table 2). Compared with children with hypoplasia and/or
dysplasia, patients with FSGS were 74% less likely, those with
HUS 52% less likely, those with MPGN 80% less likely and
those with HSP/IgA 68% less likely to receive a transplant
pre-emptively when compared with receiving a transplant
while being on dialysis for more than a year. However, when
a patient started on dialysis, there were no differences
between the different causes of renal failure with respect to
receiving a transplant after short-term dialysis or dialysis for
more or less than 1 year, except among patients with SLE. In
addition, patients with FSGS and SLE received a transplant
from a deceased donor signiﬁcantly more often than from a
living donor (OR 1.65, 95% CI 1.16–2.34, respectively, 3.50
95% CI 1.14–10.8) when compared with children with hypo-
plasia and/or dysplasia.
Risk of graft loss
Patients with FSGS had the highest risk of graft loss in the
ﬁrst year after transplantation namely 14.7%, Table 3. Patients
with other kidney diseases lost their graft in 6.8% (HSP/IgA)
and 10.1% (MPGN) of the cases, which was not signiﬁcantly
different from those with hypoplasia and/or dysplasia (6.4%),
Figure 1.
After 5 years, 32.4% of the patients with MPGN had suf-
fered from a graft loss, which was considerably higher than
among those with hypoplasia and/or dysplasia (14.4%),
Table 4, while the risk among patients with FSGS was 25.7%.
The patterns of graft loss differed between the different
causes of renal failure, while the risks of graft loss for
example due to FSGS (Figure 1A) was very high in the ﬁrst
year and were more stable thereafter, the risk of graft loss in
MPGN was consistently high over time (Figure 1C).
Focal and segmental glomerulosclerosis
Patients with FSGS who started RRT during puberty (>12)
had a signiﬁcantly higher 5-year risk of graft loss (32.4%)
when compared with those who started RRT before the age
of 6 (17.1%), Figure 1A. Patients with FSGS who started RRT
between the ages of 6 and 12 had an intermediate, but signiﬁ-
cantly increased risk of graft loss (27.7%). Relative risks for
the different age groups when compared with their peers of
the same age with hypoplasia and/or dysplasia resulted in
HRs of 1.4 for the youngest, 1.7 for those between 6–12 and
3.2 for the oldest age group (Table 4). Among patients with
FSGS who received a pre-emptive transplantation the risks of
graft loss were very similar (5.8% at 1 year and 22% at 5
years) when compared with the overall FSGS group; however,
numbers were small.
Haemolytic uraemic syndrome
The 5-year risk of graft loss among patients with HUS was
18.9%. Patients with HUS who started RRT before the age of
6 had a higher risk (21.9%) of graft loss at 5 years than those
who had started thereafter (16.5%), Figure 1B. The risk of 1-
year graft loss signiﬁcantly decreased among patients over
time (17.1% in 1995–1999 to 3.6% in 2005–2009, P = 0.03).
This decrease was not associated with a change in the
number of transplanted patients in absolute terms or relative
to the number of patients with hypoplasia and/or dysplasia.
Membranoproliferative glomerulonephritis
When studying MPGN Type I and Type II separately, we
found that the risk of 5-year graft loss was 23.5% for MPGN
Type I and 67.5% among patients with Type II,
Figure 1C. Although the rates between both types were sig-
niﬁcantly different from patients with hypoplasia and/or dys-
plasia, they were not signiﬁcantly different from each other.
Systemic lupus erythomatosus
Patients with SLE had a slightly but not signiﬁcantly in-
creased risk of graft loss (20.3% at 5 years). However, after
adjustment for the lower rate of living donation and pre-
emptive transplantation, surprisingly the differences between
SLE and hypoplasia and/or dysplasia patients were signiﬁ-
cant, showing a 3-fold increased risk of graft loss for SLE
patients when compared with those with hypoplasia and/or
dysplasia (Table 4).
HSP/IgA nephropathy
Patients with HSP/IgA had no increased risk of graft loss
when compared with patients with hypoplasia and/or dyspla-
sia. There were no differences between patients with HSP
alone when compared with those with IgA nephropathy.
DISCUSSION
Patients with FSGS and MPGN had a signiﬁcantly higher
risk of graft loss when compared with patients with hypopla-
sia and/or dysplasia. There were large differences in the
pattern of graft loss; while patients with FSGS mainly suffered
from graft loss shortly after transplantation, patients with
MPGN had a consistently high rate of graft loss independent
from time since transplantation. The risk of graft loss was not
increased for patients with HSP/IgA nephropathy. All
patients received a pre-emptive transplant less often than
patients with hypoplasia and/or dysplasia, and patients with
FSGS or SLE received an organ from a living donor less often
in comparison with patients with hypoplasia and/or dyspla-
sia. We will discuss the results separately for each disease.
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Focal and segmental glomerulosclerosis
After 5 years, over a quarter of the patients with FSGS had
lost their renal allograft, which is equal to the fraction re-
ported in previous studies, and very close to that reported
also among adult patients [6, 7]. There was a strong differ-
ence in graft survival between patients who were below the
age of 6 at the start of RRT and those who started during
puberty. Very young patients with FSGS more often have
genetic or congenital forms of FSGS, which might less often
lead to a recurrence. Unfortunately, no information on the
genetic background of the patients was available. Other
studies have also suggested higher risks of graft loss among
adolescents than among younger patients, with a lower risk
again among the adult population [1, 8].
Haemolytic uraemic syndrome
Patients with HUS had an increased risk of graft failure.
However, this increased risk only reached signiﬁcance in the
1994–1999 period. Since then there has been a big improve-
ment in graft survival. Recommendations not to perform
transplantations (from living related donors) in patients with
atypical HUS [9] may have resulted in a selection towards
more patients with typical HUS. Furthermore, genetic screen-
ing of patients with atypical HUS for abnormalities in speciﬁc
Table 1. Baseline characteristics
Number of
patients
Age at start RRT Mean
(p5–p95)
Age at transplant Mean
(p5–p95)
%
females
FSGS 407 9.7 (2.4–16.8) 11.4 (3.5–18.4) 47.7
HUS 197 8.2 (0.8–17.5) 10.1 (2.5–18.5) 54.8
SLE 40 13.8 (7.6–18.8) 15.9 (8.6–19.6) 77.5
MPGN 93 12.0 (3.6–18.8) 13.7 (4.9–19.2) 45.2
HSP/IgA 122 14.0 (6.7–18.9) 15.3 (9.5–19.4) 40.2
Hypoplasia and/or
dysplasia
1048 8.6 (0.14–17.1) 10.3 (1.9–18.1) 33.0
Bold values denote signiﬁcant difference from hypoplasia and/or dysplasia (P < 0.05).
FSGS, focal and segmental glomerulosclerosis; HUS, haemolytic uraemic syndrome; SLE, systemic lupus erythomatosus; MPGN,
membranoproliferative glomerulonephritis type I or II; HSP/IgA, IgA nephropathy or Henoch Schönlein Purpura.
Table 2. Transplant characteristics for patients with different causes of renal failure, and odds
ratios for (i) receiving a transplant from a deceased versus a living donor; (ii) receiving a
transplant pre-emptively compared with >1 year on dialysis or (iii) within a year on dialysis
compared with >1 year on dialysis, adjusted for age at start of RRT, gender and period
Percentages Odds ratios
% Living
donora
% Pre-
emptive Tx
Deceased versus living
donora,b
Pre-emptive txb Tx after dialysis <1
yearb
FSGS 29.3 9.1 1.65 (1.16–2.34) 0.26 (0.18–0.39) 0.99 (0.76–1.33)
HUS 34.7 12.2 1.22 (0.80–1.86) 0.48 (0.29–0.77) 1.17 (0.81–1.68)
SLE 16.7 10.0 3.50 (1.14–10.8) 0.20 (0.07–0.60) 0.36 (0.16–0.82)
MPGN 45.7 8.6 0.82 (0.44–1.53) 0.22 (0.10–0.48) 0.89 (0.55–1.45)
HSP/IgA 43.8 13.1 1.00 (0.60–1.66) 0.32 (0.18–0.59) 1.04 (0.68–1.62)
Hypoplasia and/or
dysplasia
41.0 26.1 1 1 1
Bold values denote signiﬁcant difference from hypoplasia and/or dysplasia (P < 0.05).
OR, odds ratio; FSGS, focal and segmental glomerulosclerosis; HUS, haemolytic uraemic syndrome; SLE, systemic lupus erythomatosus;
MPGN, membranoproliferative glomerulonephritis Type I or II; HSP/IgA, IgA nephropathy or Henoch Schönlein Purpura.
aInformation on living versus deceased donation was available for 55.6% of the patients.
bAdjusted for age, gender and time period.
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complement regulating proteins is increasingly performed
and a genetic disease cause can now be identiﬁed in 50–70%
of cases [10, 11]. Since the number of patients with HUS re-
ceiving a transplantation did not change, current practice will
have most likely led to a improved risk stratiﬁcation, resulting
in a lower number of patients with a high-risk proﬁle receiv-
ing a transplant and an increased number of transplants in
those with a low-risk proﬁle.
Unfortunately, our data did not allow the distinction
between patients with typical and atypical HUS. We tried to
distinguish between these groups by studying two different
age groups as traditionally young age at onset was an indi-
cator for typical HUS. However, we found a higher risk of
graft loss among patients who started RRT before the age of
6, while the risk among those who were above 6 years was
very similar to that among patients with hypo- or dysplasia.
Recently, Geerdink et al. also showed that nearly half of the
patients with atypical HUS ﬁrst manifest before the age of 5,
questioning age as a valuable marker for the type of HUS
[12]. Early onset atypical HUS might be an even more aggres-
sive form, explaining the high risk of graft loss.
Systemic lupus erythomatosus
There was a tendency towards increased graft loss among
patients with SLE, although it was not signiﬁcantly different
from that of patients with hypoplasia and/or dysplasia. Our
results were similar to those found in adults, but these varied
widely as 5-year graft survival has been shown to be between
69 and 91% [13–15]. Nevertheless, the tendency towards an
increased risk of graft loss was worse than expected given the
potential for current immunosuppressive regimens to main-
tain remission [1].
Membranoproliferative glomerulonephritis
MPGN is usually divided into Type I and II on the basis
of ultrastructural features [16, 17]. It has been suggested,
however, that differences in recurrence rates may be more
related to the severity of the disease than to the underlying
Table 3. One-year risk of graft loss for speciﬁc causes of renal failure
Number at
risk at 1 year
1-year
graft loss
(%)
HR—1-year graft
loss
HR—1-year graft
lossa
HR—1-year graft
lossa,b
FSGS 304 14.7 2.44 (1.71–3.48) 2.46 (1.72–3.55) 1.75 (0.98–3.13)
≤6 years at the
start of RRT
84 11.7 1.71 (0.86–3.40) 1.79 (0.84–3.82) 1.37 (0.42–4.45)
6–12 years at the
start of RRT
121 14.2 1.93 (1.08–3.40) 1.88 (1.04–3.40) 2.03 (0.74–5.58)
>12 years at the
start of RRT
101 17.4 4.38 (2.28–8.43) 4.61 (2.35–9.04) 2.18 (0.80–5.94)
HUS 149 7.5 1.17 (0.66–2.09) 1.18 (0.66–2.11) 1.17 (0.52–2.60)
≤6 years at the
start of RRT
71 9.4 1.33 (0.60–2.96) 1.47 (0.62–3.48) 2.05 (0.63–6.68)
>6 years at the
start of RRT
79 5.9 0.97 (0.41–2.28) 1.00 (0.42–2.38) 0.64 (0.15–2.77)
SLE 31 10.2 1.74 (0.64–4.79) 1.94 (0.59–5.48) 1.80 (0.51–6.42)
MPGN 74 10.1 1.61 (0.80–3.24) 1.70 (0.84–3.46) 1.01 (0.30–3.41)
MPGN Type I 48 13.3 2.15 (1.03–3.87) 2.64 (1.23–5.66) 2.05 (0.60–7.07)
MPGN Type II 26 4.7 0.54 (0.07–3.87) 0.60 (0.08–4.33) Not possible to
estimate
HSP/IgA 97 6.8 1.10 (0.59–2.29) 1.22 (0.57–2.59) 0.71 (0.21–2.12)
Hypoplasia and/or
dysplasia
869 6.4 1 1 1
Bold values denote signiﬁcant difference from hypoplasia and/or dysplasia (P < 0.05).
HR, Hazard Ratio; FSGS, focal and segmental glomerulosclerosis; RRT, renal replacement therapy; HUS, haemolytic uraemic syndrome;
SLE, systemic lupus erythomatosus; MPGN, membranoproliferative glomerulonephritis Type I or II; HSP/IgA, IgA nephropathy or
Henoch Schönlein Purpura.
aAdjusted for age at start of RRT, age at transplantation, gender and era of transplantation.
bAdditionally adjusted for living versus deceased donation, information on living versus deceased donation was available for 55.6% of the
patients.
O
R
IG
IN
A
L
A
R
T
IC
L
E
S
G r a f t l o s s a m o n g h i g h - r i s k d i s e a s e s
1035
ultrastructural features [17]. We found a higher risk of graft
loss at 5 years among patients with dense deposit disease
which was similar to that found in previous studies per-
formed in the 1980s [18]. The low graft loss among patients
with MPGN Type I was similar to that reported in other
studies among adult patients [6, 19]. Differences between
MPGN Type I and II did not reach statistical signiﬁcance due
to the small number of patients with MPGN Type II. Unlike
the other causes of renal failure, the rate of graft loss did not
improve over time in the years since transplantation. Previous
studies suggested a 50% reduced risk of graft loss among
patients with an organ from a living-related donor [18],
which possibly also explains the slightly higher proportion of
patients who received an organ from a living donor.
However, adjustment for living versus deceased donation did
not affect the risk estimates suggesting a very low advantage
of a living donation among patients with MPGN when com-
pared with that among patients with hypoplasia and/or
dysplasia.
IgA nephropathy or Henoch Schönlein Purpura
Even though previous studies have reported recurrence
rates of around 33% (range 9–61%) for patients with HSP/
IgA nephropathy [16], many studies, among adult patients,
have shown that this does not affect graft survival [6, 20].
Our data also show that the risk of graft loss (16.3%) was
very similar to that among patients with hypoplasia and/or
dysplasia. Little is known about the rate of actual graft loss in
these children, but in adults 5-year graft loss rates have been
reported of 16–30% [20–23].
LIMITATIONS
In this study, we investigated whether the risk of graft loss
was increased among children suffering from causes of renal
failure with a high rate of recurrence of the primary disease
in the transplantations. We compared those risks with the
risk among patients with hypoplasia and/or dysplasia.
Although patients with hypoplasia and/or dysplasia do not
have higher risks of graft loss due to disease recurrence, there
might be other factors affecting the risk of graft loss. Many
patients with hypoplasia and/or dysplasia are diagnosed an-
tenatally and disease progression is typically slower and more
predictable than patients with glomerulopathy, making these
conditions more amenable to pre-emptive transplantation.
There was quite a large group of patients in whom infor-
mation on whether the received kidney was from a living or a
deceased donor was missing. This might have affected the
results of the sensitivity analyses.
In this study, we cannot say whether an increased risk of
graft loss is actually related to a recurrence of the disease or
whether other factors are involved. Conversely, we do not
have information on disease recurrence without graft loss.
Nevertheless, we believe that most of the additional risk when
compared with hypoplasia and/or dysplasia will have been
caused by a recurrence of the disease.
Finally, children become adults. Although for some of the
patients we had follow-up data into adulthood, this infor-
mation was not available for all. There has been debate on
the presence of an increased graft loss after transfer to adult-
hood [23, 24], although opposed by others [25], and if this
F IGURE 1 : Graft survival among speciﬁc causes of end-stage renal disease compared with patients with hypoplasia and/or dysplasia. The
curves have been adjusted for competing risks, namely death. (A and B) Separate curves for those children starting on RRT according to
different age groups for patients with FSGS (A) and HUS (B). (C) Separate curves for patients with MPGN Type I and II (dense deposit
disease). (D) Curves for patients with HSP/IgA and SLE. FSGS, focal and segmental glomerulosclerosis; RRT, renal replacement therapy;
HUS, haemolytic uraemic syndrome; SLE, systemic lupus erythomatosus; MPGN, membranoproliferative glomerulonephritis Type I or II;
HSP/IgA, IgA nephropathy or Henoch Schönlein Purpura.
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were the case we might have underestimated the actual risk of
graft loss for all causes of renal failure.
CONCLUSION
Graft loss remains a major problem in children living with a
renal allograft. This large study was able to determine the
actual rate of graft loss for many of the rare diseases in whom
graft loss is feared to be high. In dense deposit disease,
MPGN Type I and FSGS requiring RRT after the age of 6 the
risk of graft loss is extremely high. Conversely, we were able
to show that among some of these causes of renal failure the
rate of graft loss is not increased.
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C. Afonso, G. Mircescu, L. Garneata, E.A. Molchanova, N.A.
Tomilina, B.T. Bikbov, M. Kostic, A. Peco-Antic, D. Kruscic,
S. Puric, B. Spasojevic-Dimitrijeva, G. Milosevski-Lomic,
D. Paripovic, L. Podracka, G. Kolvek, J. Buturovic-Ponikvar,
G. Novljan, N. Battelino, A. Alonso Melgar and the Spanish
Pediatric Registry, S. Schön, K.G. Prütz, B. Rippe,
Table 4. 5-year risk of graft loss for speciﬁc causes of renal failure
Number atrisk
at 5 years
5-year
graftloss (%)
HR—5-yeargraft
loss
HR—5-yeargraft
lossa
HR—5-yeargraft
lossa,b
FSGS 138 25.7 2.09 (1.59–2.75) 2.04 (1.54–2.70) 2.20 (1.37–3.52)
≤6 years at the
start of RRT
51 17.1 1.46 (0.80–2.67) 1.36 (0.70–2.64) 1.01 (0.34–3.02)
6–12 years at the
start of RRT
65 27.7 1.58 (1.04–2.40) 1.72 (1.13–2.64) 2.43 (1.11–5.29)
>12 years at the
start of RRT
22 32.4 3.51 (2.15–5.72) 3.17 (1.92–5.24) 3.75 (1.61–8.75)
HUS 55 18.9 1.28 (0.84–1.94) 1.39 (0.91–2.12) 1.90 (1.05–3.44)
≤6 years at the
start of RRT
29 21.9 1.83 (1.00–3.34) 1.96 (1.01–3.83) 3.43 (1.33–8.89)
>6 years at the
start of RRT
26 16.5 0.96 (0.53–1.77) 1.08 (0.58–1.98) 0.88 (0.31–2.56)
SLE 9 20.3 1.84 (0.86–3.94) 1.58 (0.72–3.44) 3.21 (1.19–8.69)
MPGN 27 32.4 2.36 (1.51–3.70) 2.15 (1.36–3.40) 2.73 (1.31–5.71)
MPGN Type I 25 23.5 1.95 (1.10–3.46) 1.91 (1.06–3.44) 2.76 (1.14–6.67)
MPGN Type II 2 67.5 3.34 (1.75–6.38) 2.68 (1.38–5.23) 2.70 (0.91–7.98)
HSP/IgA 28 16.3 1.12 (0.64–1.94) 1.08 (0.61–1.91) 0.90 (0.34–2.37)
Hypoplasia and /
or dysplasia
401 14.4 1 1 1
Bold values denote signiﬁcant difference from hypoplasia and/or dysplasia (P < 0.05).
HR, hazard ratio; FSGS, focal and segmental glomerulosclerosis; RRT, renal replacement therapy; HUS, haemolytic uraemic syndrome;
SLE, systemic lupus erythomatosus; MPGN, membranoproliferative glomerulonephritis Type I or II; HSP/IgA, IgA nephropathy or
Henoch Schönlein Purpura.
aAdjusted for age at start of RRT, age at transplantation, gender, and era of transplantation.
bAdditionally adjusted for living versus deceased donation, information on living versus deceased donation was available for 55.6% of the
patients.
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M. Herthelius, L. Backmän, S. Rossi, E. Maurer,
B. Schnarwyler, G. Laube, C.E. Kuenhi, A. Hoitsma,
A. Hemke, and all centres participating in the RICHQ study,
R. Topaloglu, O. Sollemezoglu, A. Duzova, D. Ivanov,
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